Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
August 5, 2015 4:54 PM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).
The Company also provided program updates and reiterated full-year 2015 net cash spend guidance of $100 million to $110 million.
Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015, compared to $169.1 million at December 31,... More
